Table 1.
Demographic and clinical characteristics of study participants at baseline.
| Controls n = 26 |
CIS n = 21 |
RRMS n = 26 |
SPMS n = 21 |
PPMS n = 26 |
|
|---|---|---|---|---|---|
| Gender (F:M) | 17:9 | 13:8 | 17:9 | 12:9 | 11:15 |
| Mean age (± SD) | 42 (10.5) | 35 (9) | 40 (10) | 51 (10) | 51 (9) |
| Mean disease duration (years/months for CIS) |
N/A | 5 | 7 | 19 | 10 |
| Mean CSA (± SD) — PropSeg (C2/C3) | 70.2 (7.4) | 75.9 (7.9) | 68.6 (7.7) | 56.2 (10.1) | 61.1 (9.3) |
| Mean CSA (± SD) — AS (C2/C3) | 75.8 (7.7) | 82.0 (8.2) | 74.0 (7.3) | 62.0 (10.5) | 67.1 (10.6) |
| Mean CSA (± SD) — PropSeg (C2/C5) | 72.4 (7.1) | 77.9 (7.9) | 71.3 (7.9) | 58.2 (10.0) | 62.5 (9.0) |
| Mean CSA (± SD) — AS (C2/C5) | 78.7 (7.4) | 84.7 (8.0) | 77.5 (8.0) | 64.4 (10.4) | 69.8 (9.7) |
| Median EDSS (range) | N/A | 1 (0–3.5) | 3 (0–6.5) | 7 (4.5–7.5) | 6 (2–7) |
| Median TWT (range) | 5 (4–6) | 4.6 (3.4–9.8) | 5.7 (3.4–9.6) | 22.3 (5–180) | 8.3 (5–180) |
| Median HPT (range) | 18.9 (15.1–27.1) | 20.7 (16.6–25.4) | 20.5 (15–36.4) | 29.6 (19.1–200.8) | 28.9 (17.1–179.6) |
| Mean PASAT (± SD) | 53 (5.3) | 45.2 (9.4) | 41.6 (14.6) | 37 (19.2) | 34.9 (18.8) |
| Median ASIA-m (range) | 100 (–) | 100 (98–100) | 99 (74–100) | 87 (63–98) | 85 (54–100) |
| Median ASIA-s (range) | 112 (–) | 112 (84–112) | 110 (98–112) | 104 (84–112) | 101.5 (90–112) |
CIS: clinically isolated syndrome; RRMS: relapsing remitting MS; PPMS: primary progressive MS; SPMS: secondary progressive MS; EDSS: expanded disability status score; TWT: 25-foot timed walk test; HPT: 9-hole peg test; PASAT: 3 s paced auditory serial addition test B; ASIA: American Spinal Injury Association motor (m) and sensory (s) scores; SD: standard deviation.